FIELD: biotechnology.
SUBSTANCE: method of enhancing neurocognitive function in a mammal having a lysosomal storage disease is described, comprising: intrathecal administration to the mammal of a composition containing an amount of recombinant adeno-associated virus (rAAV) containing an open reading frame encoding alpha-L-iduronidase or iduronate-2-sulfatase effective to enhance neurocognitive function in a mammal compared to a mammal having a lysosomal storage disease that has not been administered rAAV, wherein the rAAV has capsid rAAV9 or rAAVrh10.
EFFECT: invention expands the arsenal of means for enhancing neurocognitive function in a mammal.
21 cl, 42 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADENO-ASSOCIATED VIRUS VECTOR FOR THERAPEUTIC DELIVERY INTO THE CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2751952C2 |
| ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO CENTRAL NERVOUS SYSTEM | 2014 |
|
RU2692251C2 |
| ADENO-ASSOCIATED VIRUS-MEDIATED GENE TRANSFER INTO THE CENTRAL NERVOUS SYSTEM | 2014 |
|
RU2801511C1 |
| COMPOSITIONS AND METHODS OF TREATING MPS1 | 2014 |
|
RU2708318C2 |
| COMPOSITIONS, METHODS AND APPLICATIONS OF GENE TRANSFER FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2017 |
|
RU2805606C2 |
| METHODS AND COMPOSITIONS FOR BRAIN DISEASES TREATMENT | 2014 |
|
RU2664471C2 |
| ADENO-ASSOCIATED VIRUS VECTOR | 2015 |
|
RU2743382C2 |
| INTRATHECAL ADMINISTRATION OF VECTORS BASED ON ADENO ASSOCIATED VIRUSES FOR GENE THERAPY | 2016 |
|
RU2775138C2 |
| AAV-BASED HUNTINGTON'S DISEASE TREATMENT | 2017 |
|
RU2749971C2 |
| VECTORS AND SEQUENCES FOR TREATING DISEASES | 2011 |
|
RU2588667C2 |
